Changes in Novel Biomarkers of Disease Activity in Juvenile and Adult Dermatomyositis Are Sensitive Biomarkers of Disease Course

Overview

Journal Arthritis Rheum

Specialty Rheumatology

Date 2012 Aug 14

PMID 22886447

Citations 39

Authors

Ann M Reed

Erik Peterson

Hatice Bilgic

Steven R Ytterberg

Shreyasee Amin

Molly S Hein

Cynthia S Crowson

Floranne Ernste

Emily Baechler Gillespie

Affiliations

Soon will be listed here.

Abstract

Objective: Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)-dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM.

Methods: Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole-blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin-6 (IL-6).

Results: Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, P = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, P < 0.001 and r = 0.50, P < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (P = 0.002, P < 0.001, P = 0.095, P < 0.001). Serum levels of IL-6, IL-8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (P < 0.05).

Conclusion: Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL-6, IL-8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.

Citing Articles

Macrophage involvement in idiopathic inflammatory myopathy: pathogenic mechanisms and therapeutic prospects.

Li Z, Liu H, Xie Q, Yin G J Inflamm (Lond). 2024; 21(1):48.

PMID: 39593038 PMC: 11590228. DOI: 10.1186/s12950-024-00422-w.

Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis.

Sparling A, Ward J, Sarkar K, Schiffenbauer A, Noroozi Farhadi P, Smith M Arthritis Res Ther. 2024; 26(1):196.

PMID: 39529136 PMC: 11552237. DOI: 10.1186/s13075-024-03421-7.

Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease.

Niu Y, Liu S, Qiu Q, Fu D, Xiao Y, Liang L Arthritis Res Ther. 2024; 26(1):184.

PMID: 39468670 PMC: 11520069. DOI: 10.1186/s13075-024-03415-5.

TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of Myositis.

Wu Y, Deshpande A, Geraci N, Budde P, Sellers V, Velisetty P Arthritis Rheumatol. 2024; 77(2):190-201.

PMID: 39279150 PMC: 11782111. DOI: 10.1002/art.42989.

Epi-revolution in rheumatology: the potential of histone deacetylase inhibitors for targeted rheumatoid arthritis intervention.

Pai P, Vijeev A, Phadke S, Shetty M, Sundara B Inflammopharmacology. 2024; 32(4):2109-2123.

PMID: 38714604 PMC: 11300544. DOI: 10.1007/s10787-024-01486-z.

References

Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier J, Figarella-Branger D . Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 2005; 31(1):70-9. DOI: 10.1111/j.1365-2990.2004.00591.x. View

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

Rider L, Schiffenbauer A, Zito M, Lim K, Ahmed A, Zemel L . Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem. 2002; 48(10):1681-8. View

Niewold T, Kariuki S, Morgan G, Shrestha S, Pachman L . Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009; 60(6):1815-24. PMC: 2697261. DOI: 10.1002/art.24555. View

De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A . Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child. 1993; 69(2):232-5. PMC: 1029465. DOI: 10.1136/adc.69.2.232. View

Rider L, Koziol D, Giannini E, Jain M, Smith M, Whitney-Mahoney K . Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010; 62(4):465-72. PMC: 2924143. DOI: 10.1002/acr.20035. View

Culton D, OConner B, Conway K, Diz R, Rutan J, Vilen B . Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol. 2006; 176(2):790-802. PMC: 3709567. DOI: 10.4049/jimmunol.176.2.790. View

Miller F, Rider L, Chung Y, Cooper R, Danko K, Farewell V . Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001; 40(11):1262-73. DOI: 10.1093/rheumatology/40.11.1262. View

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

10.

Isenberg D, Allen E, Farewell V, Ehrenstein M, Hanna M, Lundberg I . International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2003; 43(1):49-54. DOI: 10.1093/rheumatology/keg427. View

11.

De Bleecker J, De Paepe B, Vanwalleghem I, Schroder J . Differential expression of chemokines in inflammatory myopathies. Neurology. 2002; 58(12):1779-85. DOI: 10.1212/wnl.58.12.1779. View

12.

Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S . Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med. 2008; 47(18):1593-9. DOI: 10.2169/internalmedicine.47.0967. View

13.

Lopez De Padilla C, Vallejo A, McNallan K, Vehe R, Smith S, Dietz A . Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007; 56(5):1658-68. DOI: 10.1002/art.22558. View

14.

Walsh R, Kong S, Yao Y, Jallal B, Kiener P, Pinkus J . Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007; 56(11):3784-92. PMC: 2443782. DOI: 10.1002/art.22928. View

15.

Bloom B, Tucker L, Miller L, Schaller J . von Willebrand factor in juvenile dermatomyositis. J Rheumatol. 1995; 22(2):320-5. View

16.

Liao A, Salajegheh M, Nazareno R, Kagan J, Jubin R, Greenberg S . Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2010; 70(5):831-6. DOI: 10.1136/ard.2010.139949. View

17.

Bilgic H, Ytterberg S, Amin S, McNallan K, Wilson J, Koeuth T . Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009; 60(11):3436-46. DOI: 10.1002/art.24936. View

18.

Rider L, Giannini E, Brunner H, Ruperto N, James-Newton L, Reed A . International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004; 50(7):2281-90. DOI: 10.1002/art.20349. View

19.

Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P . Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003; 137(1-2):125-33. DOI: 10.1016/s0165-5728(03)00032-8. View

20.

Baechler E, Bauer J, Slattery C, Ortmann W, Espe K, Novitzke J . An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007; 13(1-2):59-68. PMC: 1869622. DOI: 10.2119/2006-00085.Baechler. View